INS and diabetes mellitus: The use of CGM in people with insulin-treated diabetes has been shown to improve HbA1c, increase time spent in the target glucose range of 3.9 to 10 mmol/L, reduce risk of hypoglycaemia, and improve patient-reported outcome measures (10, 11).